ProCE Banner Activity

CITADEL-205: Phase II Study of Parsaclisib in Patients With BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma

Slideset Download
Conference Coverage
Parsaclisib, a first-in-class selective PI3Kδ inhibitor, demonstrated promising efficacy and safety in patients with BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.

Released: December 14, 2021

Expiration: December 13, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation